Literature DB >> 20209478

Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins.

Eric Vittinghoff1, Charles E McCulloch, Claudine Woo, Steven R Cummings.   

Abstract

The best information about the benefits of long-term treatment is obtained from a long-term placebo-controlled trial. However, once efficacy has been demonstrated in relatively brief trials, it may not be possible to conduct long-term placebo-controlled trials, for ethical or practical reasons. This paper presents a method for estimating long-term effects of a treatment from a placebo-controlled trial in which some participants originally randomized to active-treatment volunteer to continue on treatment during an extension study, but follow-up of participants originally assigned to placebo ends with the trial, or they are crossed over to active treatment during the extension. We propose using data from the trial to project the outcomes for a 'virtual twin' for each active-treatment volunteer under the counterfactual placebo condition, and using bootstrap methods for inference. The proposed method is validated using simulation, and applied to data from the Fracture Intervention Trial and its extension, FLEX.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20209478     DOI: 10.1002/sim.3870

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Precision Surgical Therapy for Adenocarcinoma of the Esophagus and Esophagogastric Junction.

Authors:  Thomas W Rice; Min Lu; Hemant Ishwaran; Eugene H Blackstone
Journal:  J Thorac Oncol       Date:  2019-08-20       Impact factor: 15.609

2.  In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.

Authors:  Adrianne L Jenner; Tyler Cassidy; Katia Belaid; Marie-Claude Bourgeois-Daigneault; Morgan Craig
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

3.  Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.

Authors:  Socrates Papapoulos; Roland Chapurlat; Cesar Libanati; Maria Luisa Brandi; Jacques P Brown; Edward Czerwiński; Marc-Antoine Krieg; Zulema Man; Dan Mellström; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; José A Román Ivorra; Christian Roux; Eric Vittinghoff; Matthew Austin; Nadia Daizadeh; Michelle N Bradley; Andreas Grauer; Steven R Cummings; Henry G Bone
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

4.  Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.

Authors:  J-Y Reginster; J-M Kaufman; S Goemaere; J P Devogelaer; C L Benhamou; D Felsenberg; M Diaz-Curiel; M-L Brandi; J Badurski; J Wark; A Balogh; O Bruyère; C Roux
Journal:  Osteoporos Int       Date:  2011-11-29       Impact factor: 4.507

5.  Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.

Authors:  H G Bone; D W Dempster; J A Eisman; S L Greenspan; M R McClung; T Nakamura; S Papapoulos; W J Shih; A Rybak-Feiglin; A C Santora; N Verbruggen; A T Leung; A Lombardi
Journal:  Osteoporos Int       Date:  2014-11-29       Impact factor: 4.507

6.  Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.

Authors:  Jonathan D Adachi; Henry G Bone; Nadia S Daizadeh; Paula Dakin; Socrates Papapoulos; Peyman Hadji; Chris Recknor; Michael A Bolognese; Andrea Wang; Celia J F Lin; Rachel B Wagman; Serge Ferrari
Journal:  BMC Musculoskelet Disord       Date:  2017-04-27       Impact factor: 2.362

7.  The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.

Authors:  Henry G Bone; Roland Chapurlat; Maria-Luisa Brandi; Jacques P Brown; Edward Czerwinski; Marc-Antoine Krieg; Dan Mellström; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; Jose A Román Ivorra; Christian Roux; Eric Vittinghoff; Nadia S Daizadeh; Andrea Wang; Michelle N Bradley; Nathalie Franchimont; Michelle L Geller; Rachel B Wagman; Steven R Cummings; Socrates Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.